Life Sciences Tools and Services

Bio-S

Bio-S released FY2026 Q4 earnings on April 23 (BJT), actual revenue CNY 160.46 M, actual EPS CNY 0.1181

Bio-S released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 128.73 M, actual EPS CNY -0.24

Bio-S to Release FY2026 Q1 Earnings on April 24 After-Market (BJT)

Bio-S to Release FY2025 Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 730 M, EPS CNY 0.49

Bio-S released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 177.53 M, actual EPS CNY 0.0303

Bio-S released FY2025 9 Months Earnings on October 24 After-Market (BJT), with actual revenue of CNY 509.88 M and EPS of CNY 0.0911

Bio-S to Release FY2025 Q3 Earnings on October 25 After-Market (BJT)

Insilico Medicine Signs Drug Development Cooperation Agreement with BCI Pharma

Bio-S released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 203.63 M, actual EPS CNY 0.3008

Bio-S released FY2025 Semi-Annual earnings on August 26 After-Market BJT, actual revenue CNY 332.35 M, actual EPS CNY 0.03

Bio-S to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

BaiCheng Pharmaceutical Expected Sharp Decline in Net Profit for H1 2025

BaiCheng Medicine Responds to Investor Questions on Weight Loss Drugs and Belt and Road Layout

BaiCheng Pharmaceutical Adds Pet Economy Concept

Director and Executives of Biotech Pharma Increased Shareholding

Director and Executive of BaiCheng Medicine Increased Holdings by 3,000 Shares

Controlling shareholder Lou Jinfang plans to 增持百诚医药股份

Beicheng Pharmaceutical Adds Ophthalmology Concept and Announces Q1 2025 Earnings

BaiCheng Medicine's Subsidiary Lays Out Veterinary and Pet Drug R&D

BaiCheng Medicine Secretary Answers Investor Questions on AI Platform and Investment

301096

Bio-S's subsidiary, Saimo Pharmaceutical, intends to win bids for 12 varieties in the 11th batch of national centralized drug procurement, demonstrating its production capacity and market competitiveness. Saimo Pharmaceutical has established GMP standard factories and laboratories, completed the landing verification of 617 projects, and registered 461 projects. This bidding win will accelerate its capacity release and further enhance its market share

Zhitong

Bio-S: Subsidiary Saimo Pharmaceutical plans to win bids for 12 varieties in the 11th national drug procurement

000892

002555

36Kr learned that the three major A-share indices opened lower collectively, with the Shanghai Composite Index down 0.02%, the Shenzhen Component Index down 0.1%, and the ChiNext Index down 0.26%; the media and CRO concepts led the gains, with SANQI HUYU hitting the daily limit, Bio-S and H&R rising over 5%; the semiconductor and optical module sectors saw the largest declines, with Baiwei Storage and Yuanjie Technology dropping over 3%; the new stock N Dana surged 447.95% on its first day of listing

36Kr

SANQI HUYU

The three major A-share indices opened lower collectively, with new stock N Danna soaring 447.95% on its first day of listing

According to the Zhitong Finance APP, Bio-S released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 510 million yuan, a year-on-year decrease of 29.33%. The net profit attributable to shareholders of the listed company was 6.1242 million yuan, a year-on-year decrease of 95.68%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 13.9173 million yuan. The basic earnings per share were 0.06 yuan

Bio-S released its performance for the first three quarters, with a net profit attributable to the parent company of 6.1242 million yuan, a decrease of 95.68%

Bio-S announced that its independently developed innovative drug BIOS-0623-Z4 tablets have received clinical trial approval from the National Medical Products Administration (NMPA). This drug targets cancer pain in adults and employs a non-opioid target mechanism, with no other drugs on the market targeting the same mechanism and indication. BIOS-0623-Z4 tablets are classified as Category 1 chemical drugs and are innovative drugs that have not been launched domestically or internationally

Bio-S: Innovative drug BIOS-0623-Z4 tablets have received clinical trial approval

688166

688658

603590

688513

300497

Innovative drug concept stocks surged and then fell back, with Mengke Pharmaceutical dropping over 10%, BrightGene, Bio-S falling over 7%, and YKYY, Konruns, EASTON BIOPHARMACEUTICALS, Fushine among those with the largest declines

BrightGene

YKYY

Konruns

EASTON BIOPHARMACEUTICALS

Fushine

02228

XTALPI rose nearly 7% in early trading, with its stock price doubling since early August, currently reported at HKD 12.37. The company signed a letter of intent for cooperation with Bio-S, and both parties will jointly promote new drug research and development using AI technology, targeting clinical needs in various disease areas. GF Securities pointed out that XTALPI, as a third-party service provider for AI-driven drug development, emphasizes technological neutrality and is expected to become an industry infrastructure in the future, with a sustainable business model and broad market space

- Jingtai Holdings (02228) saw a nearly 7% increase in early trading, with its stock price doubling since early August, currently at HKD 12.37.  
- Jingtai Technology and Baicheng Pharmaceutical (301096.SZ) signed a cooperation agreement to utilize Jingtai's "AI + robotics" platform for new drug development, addressing unmet clinical needs in various disease areas.  
- According to Guangfa Securities, Jingtai aims to be a neutral third-party service provider in AI-driven drug development, which may enhance its role as an industry infrastructure as AI integration deepens in drug discovery.

XTALPI

Understanding the Market | XTALPI rose nearly 7% in the morning session as the company signed a letter of intent for cooperation with Bio-S to jointly promote AI new drug research and development cooperation

According to the Qichacha APP, recently, the West Lake Innovation Technology Achievement Transformation Venture Capital Partnership was established, with an investment amount of approximately 500 million yuan. The business scope includes: venture capital. Qichacha's equity penetration shows that the enterprise is jointly funded by Hangzhou Mipeng Enterprise Management Partnership under Bio-S and others

Bio-S and others establish a new venture capital partnership for the transformation of scientific and technological achievements

Bio-S announced that its subsidiary Hangzhou Mipeng plans to invest 15 million yuan to subscribe for shares in West Lake Innovation (Hangzhou) Venture Capital Partnership, focusing on investments in strategic emerging industries such as biomedicine and hard technology, and concentrating on investment opportunities in early-stage and small to medium-sized enterprises

Bio-S's subsidiary Hangzhou Mipeng plans to invest 15 million yuan in a partnership enterprise to layout strategic emerging industries such as biomedicine and hard technology

Bio-S announced that directors Jia Fei, Song Bofan, Yan Hongbing, and senior management Chen An plan to reduce their holdings in the next three months. Jia Fei intends to reduce no more than 12,200 shares, accounting for 0.0112% of his holdings; Song Bofan intends to reduce no more than 2,300 shares, accounting for 0.0021% of his holdings; Yan Hongbing intends to reduce no more than 9,500 shares, accounting for 0.0088% of his holdings; Chen An intends to reduce no more than 11,200 shares, accounting for 0.0103% of his holdings

Bio-S: Jia Fei plans to reduce his holdings by 0.0112% within three months

Bio-S announced that the company's controlling shareholder, Lou Jinfang, has adjusted the upper limit of the share purchase plan from no more than 60 yuan per share to no more than 80 yuan per share, with other arrangements remaining unchanged. The original plan was to increase the company's shares through centralized bidding within 6 months starting from June 12, 2025, with a total purchase amount of no less than 50 million yuan and no more than 100 million yuan, and a total purchase ratio not exceeding 2.00%. As of the date of this announcement, Lou Jinfang has increased his holdings by 612,500 shares, accounting for 0.56% of the company's total share capital, with a purchase amount of 30.3079 million yuan

Bio-S: The upper limit for the increase in holdings is adjusted to 80 yuan

Bio-S(301096.SZ)